BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37355856)

  • 1. Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
    Bertorello N; Luksch R; Bisogno G; Haupt R; Spallarossa P; Cenna R; Fagioli F
    Pediatr Blood Cancer; 2023 Jun; ():e30515. PubMed ID: 37355856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
    de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
    Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease in survivors of childhood cancer.
    Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
    Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
    Wu V
    J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
    Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cardiotoxicity among survivors of childhood cancer.
    Hutchins KK; Siddeek H; Franco VI; Lipshultz SE
    Br J Clin Pharmacol; 2017 Mar; 83(3):455-465. PubMed ID: 27591829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
    Chen JJ; Wu PT; Middlekauff HR; Nguyen KL
    Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H213-H222. PubMed ID: 27923793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with Dexrazoxane-Anthracyclines association.
    Filomena D; Versacci P; Cimino S; Mattiucci C; Maestrini V; Cantisani D; Petronilli V; Agati L; Schiavetti A
    Int J Cardiol; 2020 Jan; 299():271-275. PubMed ID: 31422879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
    Cvetković RS; Scott LJ
    Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimizing cardiac toxicity in children with acute myeloid leukemia.
    Narayan HK; Getz KD; Leger KJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
    Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
    Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
    Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.
    Kim H; Kang HJ; Park KD; Koh KN; Im HJ; Seo JJ; Lee JW; Chung NG; Cho B; Kim HK; Lee JM; Hah JO; Lee JA; Lee YH; Park SK; Baek HJ; Kook H; Kim JY; Kim HS; Kim HM; Chueh HW; Park M; Yoon HS; Lee MJ; Choi HS; Ahn HS; Kawano Y; Park JW; Hahn S; Shin HY
    Cancer Res Treat; 2019 Jan; 51(1):357-367. PubMed ID: 29764117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
    Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
    Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.